EcoR1 Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

EcoR1 Capital’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,404,070	Closed	-$6.57M	–	31
2025 Q2	$6.57M	Hold	27,404,070	–	–	0.39%	29
2025 Q1	$5.4M	Hold	27,404,070	–	–	0.32%	30
2024 Q4	$14.8M	Hold	27,404,070	–	–	0.56%	33
2024 Q3	$26M	Hold	27,404,070	–	–	0.89%	27
2024 Q2	$26.7M	Hold	27,404,070	–	–	0.82%	26
2024 Q1	$43.3M	Buy	+27,404,070	New	+$33.1M	1.1%	22

Other funds holding ADAP

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.41B AUM 41.48% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

EcoR1 Capital's ADAP Position: Q3 2025 in Review

EcoR1 Capital sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 27,404,070 shares — an estimated $6.57M sold.

EcoR1 Capital first reported a position in ADAP in Q1 2024 and held it in 6 quarters. The position peaked at $43.3M in Q1 2024. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

EcoR1 Capital reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
EcoR1 Capital sold 27,404,070 Adaptimmune Therapeutics shares in Q3 2025, an estimated $6.57M.
EcoR1 Capital first reported a position in Adaptimmune Therapeutics in Q1 2024 and held it in 6 quarters.
EcoR1 Capital's Adaptimmune Therapeutics position peaked at $43.3M in Q1 2024.
55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on EcoR1 Capital's 13F filing for Q3 2025, filed 14 Nov 2025.